搜索
ESSA Pharma Inc
EPIX添加自选
0.201USD
0.0000.00%
收盘 07/02, 13:00（美东）报价延迟15分钟
8.93M总市值
亏损市盈率 TTM
关于 ESSA Pharma Inc 公司
ESSA Pharma Inc. 是一家加拿大临床阶段制药公司。该公司专注于开发治疗前列腺癌患者的专有疗法。其主要候选药物 Masofaniten（原名 EPI-7386）是一种口服小分子，可抑制雄激素受体 (AR) 的 N 端结构域。Masofaniten 正在开发中，用于与抗雄激素疗法联合治疗早期前列腺癌患者。该公司正在完成 Masofaniten 作为转移性去势抵抗性前列腺癌 (mCRPC) 患者的单一疗法治疗的临床开发。
ESSA Pharma Inc简介
公司代码EPIX
公司名称ESSA Pharma Inc
上市日期Feb 22, 2021
CEODr. David Ross Parkinson, M.D.
员工数量35
证券类型Ordinary Share
年结日Feb 22
公司地址999 West Broadway, Suite 720
城市VANCOUVER
上市交易所NASDAQ Capital Market Consolidated
国家Canada
邮编V5Z 1K5
电话17783310962
网址https://www.essapharma.com/
公司代码EPIX
上市日期Feb 22, 2021
CEODr. David Ross Parkinson, M.D.
ESSA Pharma Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Jon Adkins
Mr. Jon Adkins
President, Treasurer, Secretary, Director
President, Treasurer, Secretary, Director
--
--
Mr. David Sidney Wood, CPA
Mr. David Sidney Wood, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter Virsik
Mr. Peter Virsik
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
-100.00%
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
-100.00%
名称
名称/职务
职务
持股
持股变动
Mr. Jon Adkins
Mr. Jon Adkins
President, Treasurer, Secretary, Director
President, Treasurer, Secretary, Director
--
--
Mr. David Sidney Wood, CPA
Mr. David Sidney Wood, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter Virsik
Mr. Peter Virsik
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
-100.00%
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
-100.00%
常见问题
ESSA Pharma Inc的前五大股东是谁？
ESSA Pharma Inc 的前五大股东如下：Mr. Jon Adkins
有多少机构持有ESSA Pharma Inc(EPIX)的股份？
截至2025Q3，共有79家机构持有ESSA Pharma Inc的股份，合计持有的股份价值约为34.87M，占公司总股份的73.70%。与2025Q2相比，机构持股有所增加，增幅为-13442442.00。